Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aspirin
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Applied Bio Study Uncovers Major Breakthrough in Understanding and Treating Respiratory Inflammation
Details : Biovanta, an OTC product with low-dose aspirin and other anti-inflammatory ingredients, reduced inflammation when applied to affected cells and tissues, making it the first scientifically proven 100% naturally derived, OTC medicine for treating cough, co...
Product Name : Biovanta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2021
Lead Product(s) : Aspirin
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Proxalutamide,Azithromycin,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Corpometria Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The study on the effects of proxalutamide on COVID-19 has received national IRB approval and will be conducted in Brasilia, Brazil, in non-hospitalized patients with mildto-moderate COVID-19 disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 22, 2020
Lead Product(s) : Proxalutamide,Azithromycin,Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Corpometria Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Proxalutamide
Therapeutic Area : Dermatology
Study Phase : Undisclosed
Sponsor : Corpometria Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Breakthrough discovery by Applied Biology scientists paves way for a Generic Anti-androgen as a treatment for Covid-19.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 24, 2020
Lead Product(s) : Proxalutamide
Therapeutic Area : Dermatology
Highest Development Status : Undisclosed
Sponsor : Corpometria Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Applied Biology to Launch COVID-19 Drug Discovery Platform based on Breakthrough Discovery
Details : Drug discovery platform to rapidly predict blocking of covid-19 pneumocyte cellular entry.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 04, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : On the heels of discovering an association between covid-19 and androgens, applied biology to expand its research program into anti-androgen based therapies.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 13, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable